LIBERTY DENTAL GROUP acquired by OAKLEY CAPITAL INVESTMENTS

The takeover of the SAES Getters Nitinol business by Resonetics establishes a rare, end-to-end metallurgical capability within the medical CDMO landscape. By absorbing the complete production chain—from the furnace to the finished catheter component—the organization bypasses the traditional constraints of specialized material procurement. This strategic consolidation addresses a critical bottleneck in the interventional device market, where high-grade Nitinol supply often dictates project timelines. Beyond simple supply chain security, the integration enables a deeper level of innovation; the group can now customize alloy chemistry to optimize the mechanical response of next-generation stents and heart valves. This move effectively insulates the platform from upstream price volatility and technical dependencies on external metal suppliers. By merging raw alloy science with precision laser-cutting expertise, the group offers a unique, high-security value proposition to global medtech OEMs.

Luxempart acquired a substantial minority stake in Alphacaps GmbH. The deal is meticulously designed to establish a long-term, highly aligned partnership between the historical owners and the incoming financial sponsor. By providing a flexible capital solution, Luxempart injects fresh momentum into the enterprise, perfectly equipping the incumbent management team with the vital strategic backing and resources required to actively execute their ongoing development roadmap. The primary objective of this new alliance is to massively accelerate the target's expansion within the fast-growing European nutritional supplements market.

Eurazeo has completed the sale of D.O.R.C. to Carl Zeiss Meditec AG. This transaction marks the successful conclusion of a four-year transformation under Eurazeo's ownership, during which D.O.R.C. evolved from a European champion into a global platform. The strategic rationale for Zeiss is to create a comprehensive "end-to-end" offering for ophthalmologists. By integrating D.O.R.C.'s leading vitreoretinal surgical systems with Zeiss's existing portfolio of diagnostics, microscopes, and digital workflows, the combined entity becomes a one-stop-shop for eye care providers. The deal also unlocks significant cross-selling opportunities, leveraging Zeiss's massive global distribution network to accelerate the adoption of D.O.R.C.'s products in under-penetrated markets.

EQT Private Equity has agreed to sell 100% of Schülke to a consortium led by ATHOS, following a highly successful three-year transformation period. EQT originally acquired the company in a 2020 carve-out from Air Liquide for approximately €1.0 billion. During its ownership, EQT repositioned Schülke as a pure-play healthcare leader, executing five add-on acquisitions and divesting the personal care division. This strategic focus resulted in double-digit annual revenue growth and a near doubling of EBITDA in the core healthcare segment. The sale to the ATHOS Consortium represents a transition from institutional private equity to long-term family office ownership, aligning with Schülke’s 135-year heritage and its mission to protect lives worldwide.

EQT completed the take-private acquisition of Dechra Pharmaceuticals. The strategic rationale for taking Dechra private was to support its long-term growth away from the volatility of public markets. In early 2023, Dechra faced headwinds from "wholesaler de-stocking" in the US, which hit its share price. EQT intends to accelerate investment in the company's innovation pipeline and support further international acquisitions without the pressure of quarterly earnings reporting.

Elos Medtech entered into an agreement to acquire 100% of Klingel Medical Group from IK Partners and its management team. The strategic rationale for the deal is to create a market-leading European MedTech CDMO with significantly enhanced R&D capabilities and a broader technological offering. The acquisition expands Elos Medtech's industrial presence in the DACH region by adding eight specialized manufacturing sites in Germany and Switzerland. Strategically, the combination aims to unlock cross-selling opportunities and provides Klingel with increased visibility and distribution channels in the U.S. market. This milestone consolidation allows the combined entity to leverage a global footprint to drive operational improvements and cater to the unique needs of international OEM customers in the medical device sector.

Lauxera Capital Partners has successfully led a £25 million growth investment into OrganOx, marking a pivotal minority platform entry into the high-barrier medical technology sector. Based in Oxford, England, the commercial-stage enterprise represents a strategic addition to the investor's specialized healthcare portfolio. The investment thesis centers on funding the global scale-up and commercial acceleration of an established, market-leading medical device platform. OrganOx leverages a proprietary technology, normothermic machine perfusion, which has already supported over 2,500 liver transplants worldwide. The strategic rationale of the capital injection is focused on rapidly expanding OrganOx's commercial footprint and deeply institutionalizing its partnerships with tier-one transplant centers across the United States and Europe.

Novo Nordisk, the global leader in insulin production, has announced the acquisition of Biocorp, a French medtech company specialized in connected drug delivery devices. The transaction began with the acquisition of the 45.3% stake held by the main shareholder, Bio Jag, followed by a mandatory simplified tender offer for the remaining shares.

The successful acquisition of AprioMed by IZI Medical Products represents a tactical expansion of Halma’s healthcare portfolio in the interventional radiology segment. This transaction marks the integration of AprioMed’s highly specialized bone biopsy technology, effectively widening the technical operational depth available to IZI Medical’s global clinical customer base. The strategic rationale centers on the industrial synergy between AprioMed’s minimally invasive instruments and IZI Medical’s established oncology and radiology portfolio, allowing for a more verticalized patient diagnosis solution. By incorporating AprioMed, IZI Medical reinforces its ability to address the increasing demand for cancer diagnosis tools driven by an aging global population. The partnership is designed to leverage IZI Medical’s existing global distribution channels and direct international presence to drive the scaling of AprioMed’s proprietary hardware. This integration facilitates a more robust clinical platform, providing the strategic depth required to navigate the complex evolution of the global healthcare landscape. The move solidifies the group’s standing as a primary enabler of diagnostic precision and manufacturing excellence.

Sartorius Stedim Biotech has reached a definitive agreement to acquire one hundred percent of the share capital of Polyplus from private equity sponsors ArchiMed and Warburg Pincus. This landmark transaction is structured as a full buyout, effectively transferring ownership from financial sponsors to a strategic corporate acquirer. The operation is financially underpinned by a bridge loan facility secured by the acquirer's parent company through J.P. Morgan, which is expected to be ultimately refinanced via long-term financial instruments potentially incorporating an equity component. This platform investment represents a highly synergistic and value-accretive maneuver for the acquirer, structurally designed to capture a significant share of the rapidly expanding cell and gene therapy market. The acquisition introduces vital technological complementarities, specifically bridging the target's pioneering expertise in viral vector production components with the acquirer’s established portfolio of cell culture media and advanced therapy essentials. By internalizing these capabilities, the acquirer strengthens its footprint in the United States while capitalizing on a sector characterized by high structural growth and accelerating pipeline developments. The financial parameters of the transaction underscore the premium nature of the target asset, driven by an intensively competitive environment wherein proactive industrial consolidators rapidly outpaced financial sponsors during the preemptive phase of the process. The deal delivers an exceptional exit profile for the incumbent sponsors, culminating in an impressive multiple on invested capital realized over the investment holding period.